Jan 13, 2020 / 05:30PM GMT
Cory William Kasimov - JP Morgan Chase & Co, Research Division - Senior Biotechnology Analyst
All right. Good morning, everyone. My name is Cory Kasimov. I'm the senior large cap biotech analyst at JPMorgan. And it's my pleasure to introduce our next company, Gilead Sciences, and making his first presentation at the JPMorgan Healthcare Conference is new Chairman and CEO, Dan O'Day. Please note that following Dan's presentation there will be a breakout just down the hall in the Borgia Room. So good luck getting back there.
With that, I'll turn it over to Dan.
Daniel O'Day - Gilead Sciences, Inc. - Chairman & CEO
Thank you very much, Cory. Good morning, everybody. It's terrific to be here first time with Gilead. I've been here before, obviously. I'd like to just say, I'm really excited to walk through the next chapter with you.
As we turn this decade, the reasons that I came to Gilead have only been amplified over the past 10 months. And that is, when you think back to the medical breakthroughs that occurred over the
Gilead Sciences Inc at JPMorgan Healthcare Conference Transcript
Jan 13, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers